Standout Papers
Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
2014
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
2010
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
2012
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2014
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
Closing the personalized medicine information gap: HER2 test documentation practice.
2013
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
2008
Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer
2009
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
2008
Delay to formalin fixation effect on breast biomarkers
2009
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
2010
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
2008
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
2013
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
2008
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
2010
Concordance among Gene-Expression–Based Predictors for Breast Cancer
2006
Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
2008
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
2017
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
2009
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
2010
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
2009
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
2011
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
2015
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
2011
Is gene array testing to be considered routine now?
2011
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
2012
Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation
2011
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
2014
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
2013
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
2017
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
2011
Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer
2010
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
Contextual factors in shared decision making: a randomised controlled trial in women with a strong suspicion of breast cancer
2009
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
2008
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
2009
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
2010
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
2011
Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/ neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer
2008
Interactive Digital Education Aid in Breast Reconstruction
2008
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
2010
The Evolving Role of Partial Breast Irradiation in Early-Stage Breast Cancer
2013
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
2011
A view on drug resistance in cancer
2019 StandoutNature
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Chronic myeloid leukaemia as a model of disease evolution in human cancer
2007
Trastuzumab: triumphs and tribulations
2007
Decision aids for people facing health treatment or screening decisions
2011
Decision aids for patients facing health treatment or screening decisions: systematic review
1999
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Decision aids for people facing health treatment or screening decisions
2014
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
2010
Decision aids for people facing health treatment or screening decisions
2003
Effects of Decision Aids for Menorrhagia on Treatment Choices, Health Outcomes, and Costs
2002
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
2010
Preoperative Magnetic Resonance Imaging in Breast Cancer
2012
Surgical Margins in Lumpectomy for Breast Cancer — Bigger Is Not Better
2012
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
2008
Entertainment Education for Informed Breast Cancer Treatment Decisions in Low-Literate Women: Development and Initial Evaluation of a Patient Decision Aid
2006
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
2015
Evaluation of automated silver‐enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens
2009
Where is the theory? Evaluating the theoretical frameworks described in decision support technologies
2008
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
2017
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
2008
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012
Breast cancer genomes — form and function
2010
Decision aids for people facing health treatment or screening decisions
2009
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer
2003
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
2014
Surgical Management of the Breast
2013
Effect of a Decision Aid on Knowledge and Treatment Decision Making for Breast Cancer Surgery
2004
Gene expression predictors in breast cancer: Current status, limitations and perspectives
2008
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
2017
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Interventions for improving the adoption of shared decision making by healthcare professionals
2010
Decision Aids for Patients Considering Options Affecting Cancer Outcomes: Evidence of Efficacy and Policy Implications
1999
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Histopathologic variables predict Oncotype DX™ Recurrence Score
2008
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
2008
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Role of bisphosphonates in postmenopausal women with breast cancer
2013
Education and role modelling for clinical decisions with female cancer patients
2004
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
2010
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Gene-Expression Signatures in Breast Cancer
2009
Cancer immunotherapy comes of age
2011 StandoutNature
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions
2011
Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial
2011
Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?
2014
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Is there a Reliable Method to Assess the Complete Pathologic Response on the Tumor after Neo-adjuvant Chemotherapy in Inflammatory Breast Cancer toward Recommendations for the Pathologic Process? Experience in 56 Patients Treated in a Single Institution
2010
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer
2009
Heterogeneity of breast cancer and implications of adjuvant chemotherapy
2007
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
2006
Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial
2008
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Adjuvant therapies for special types of breast cancer
2011
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
2010
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
2015
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
2010
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Interpretive Review : Feasibility and Effects of Decision Aids
2000
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Chemotherapy in Early Breast Cancer: When, How and Which One?
2014
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
2010
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
2015
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
2009 Standout
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
2010
HeterogeneousHER2Gene Amplification
2011
Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance)
2015
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Preservation of Fertility in Patients with Cancer
2009 Standout
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
The cancer genome
2009 StandoutNature
Deconstructing the molecular portraits of breast cancer
2010
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
2013
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Axillary Nodal Management Following Neoadjuvant Chemotherapy
2016
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
2009
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
2006
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
2015
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
2011
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
2015
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Micrometastatic Disease and Metastatic Outgrowth: Clinical Issues and Experimental Approaches
2009
Decision aids for people facing health treatment or screening decisions
2017 Standout
Using the shortwave infrared to image middle ear pathologies
2016 StandoutNobel
Breast Cancer Treatment
2019 Standout
Interventions for improving the adoption of shared decision making by healthcare professionals
2014
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Impact of an Educational Video on Patient Decision Making in Early Breast Cancer Treatment
2006
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
2012
Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
2010
Metabolic reprogramming and cancer progression
2020 StandoutScience
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
2009
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
2012
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
2009
Informed decision making: an annotated bibliography and systematic review.
1999
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
2010
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Diffuse optical imaging using spatially and temporally modulated light
2012
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
2009
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
2015
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results
2009
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Decision Support for Patients With Early-Stage Breast Cancer: Effects of an Interactive Breast Cancer CDROM on Treatment Decision, Satisfaction, and Quality of Life
2001
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of Charles E. Geyer being referenced
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
2012
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
2014
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
2013
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
2010
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment
2009
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
2012
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
2005
The emerging role of Lapatinib in HER2-positive breast cancer
2008
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
2015
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
2011
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer
2006
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
2012
Increasing patient involvement in choosing treatment for early breast cancer
1995
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
2014
Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma
2004
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
2010
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
1999
Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31
2007
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
2010
Olympia, Neo-Olympia and Olympiad: Randomized Phase III Trials of Olaparib in Patients (Pts) with Breast Cancer (Bc) and a Germline Brca1/2 Mutation (Gbrcam)
2014
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
2017
Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer
2008
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2023
Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial
2008
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
2011
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
2017
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.
2012
Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
2009
Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H)
2007
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
2013
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
2014
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
2015
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.
2012
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.
2016
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2006
Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials
2006
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
2008
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
2013
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
2016
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
2007